RayKnowChina Research Map
Shortlist0

RecruitingMultiple myelomaAplastic anaemiaPhase not stated

Registered title, quoted from ClinicalTrials.gov

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

An open trial on multiple myeloma and aplastic anaemia, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Qinghai University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

Read the record on ClinicalTrials.gov

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Affiliated Hospital of Qinghai University青海大学附属医院XiningHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07205523, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.
  • Planned or actual hematopoietic stem cell transplantation (HSCT).
  • Provision of signed informed consent.

Exclusion Criteria:

  • Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.
  • Substance abuse compromising adherence.
  • Any condition judged by investigators to jeopardize safety or compliance.

Quoted from ClinicalTrials.gov, NCT07205523, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07205523, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07205523